Background and Objective: Gliomas are the most common primary brain tumors. Despite therapeutic advances, the majority of gliomas do not respond to either chemo or radiotherapy. CD117, the gene product of c-kit has been expressed in cells of glial tumors. Because gastrointestinal stromal tumors (GISTs) that express CD117 respond dramatically to treatment with tyrosine kinase inhibitors, ide...

Epithelioid gastrointesinal tumors (GISTs) are less likely to have c-kit gene mutations (and express CD117) than spindle cell GISTs. CD117 negative/c-kit negative GISTs can have platelet-derived growth factor alpha (PDGFRα) gene mutations, overexpress PDGFRα protein and respond to imatinib mesylate. Many cases of CD117-negative/CD117weakly positive, c-kit mutation negative and PDGFRα mutation p...

background and objective: gliomas are the most common primary brain tumors. despite therapeutic advances, the majority of gliomas do not respond to either chemo or radiotherapy. cd117, the gene product of c-kit has been expressed in cells of glial tumors. because gastrointestinal stromal tumors (gists) that express cd117 respond dramatically to treatment with tyrosine kinase inhibitors, identif...

Protein kinase signal-transduction pathways play critical roles in regulating nociception. The c-kit receptor contributes to pain regulation in the spinal cord and is present on both peripheral and central terminals. Expression of c-kit was demonstrated in human trigeminal and spinal ganglia. However, the brainstem expression of c-kit was overlooked. We aimed to evaluate it by immunohistochemis...

C-kit is a proto-oncogene located on the long arm of chromosome 4. Its product, CD117, is a specific immunohistochemical (IHQ) marker that is associated with response to a potent tyrosine kinase inhibitor therapy with STI-571 (Gleevec®) in chronic myelogenous leukemia and GISTs. In our study, we aimed to evaluate the expression of CD117 in glial tumors as this finding may guide therapeutic appr...

background : cd117 is a thyrosin kinase receptor encoded by c-kit proto-oncogene. it is expressed during normal development in some tissues and also in a subset of neoplasia especially gastrointestinal stromal tumors   (gists). treatment with thyrosin kinase inhibitors (e.g., imatinib) is useful in cd117- positive gists. the goal of this study is to investigate the expression of cd117 in glial ...

The stem cell factor (SCF) receptor CD117 (c-kit), is widely used for identification of hematopoietic stem cells and cancer stem cells. Moreover, CD117 expression in carcinoma cells indicates a poor prognosis in a variety of cancers. However the potential expression in tumor microenvironment and the biological and clinical impact are currently not reported. The expression of CD117 was immunohis...

Background—Recent studies have shown that bone marrow–derived stem cells differentiate into the phenotype of cardiomyocytes in vivo and in vitro. We tried to regenerate infarcted myocardium by implanting ex vivo transforming growth factor (TGF)–preprogrammed CD117 (c-kit)–positive (CD117 ) stem cells intramyocardially. Methods and Results—CD117 cells were isolated from the bone marrow mononucle...

BACKGROUND Recent studies have shown that bone marrow-derived stem cells differentiate into the phenotype of cardiomyocytes in vivo and in vitro. We tried to regenerate infarcted myocardium by implanting ex vivo transforming growth factor (TGF)-beta-preprogrammed CD117 (c-kit)-positive (CD117+) stem cells intramyocardially. METHODS AND RESULTS CD117+ cells were isolated from the bone marrow m...

BACKGROUND The aim of this study was to determine the incidence and role of CD117 (c-KIT) overexpression as a predictive/prognostic marker in extensive-stage small-cell lung carcinoma (ESSCLC). We performed a retrospective study on subjects with a biopsy-proven diagnosis of ESSCLC. PATIENTS AND METHODS A chart review for demographic and clinical data was performed on patients with ESSCLC diag...